Atria Investments Inc bought a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) in the 4th quarter, HoldingsChannel.com reports. The fund bought 7,978 shares of the specialty ...

About Supernus Pharmaceuticals, Inc. Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS ...

In this article, we are going to take a look at where Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) stands against the other small cap pharma stocks. Emily Field, Head of European Pharma Research ...

In other Supernus Pharmaceuticals news, SVP Jonathan Rubin sold 927 shares of the firm’s stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price ...

Supernus Pharmaceuticals CEO will participate in a fireside chat at the TD Cowen Health Care Conference on March 3, 2025. Supernus Pharmaceuticals, Inc., a biopharmaceutical company specializing ...

ROCKVILLE, Md., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ...

ROCKVILLE, Md., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ...

Cantor Fitzgerald analyst Kristen Kluska maintained a Hold rating on Supernus Pharmaceuticals (SUPN – Research Report) yesterday and set a price target of $36.00. The company’s shares closed ...

Piper Sandler analyst David Amsellem reiterated a Hold rating on Supernus Pharmaceuticals (SUPN – Research Report) today and set a price target of $36.00. The company’s shares closed yesterday ...

ROCKVILLE, Md., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ...

Good afternoon, and welcome to Supernus Pharmaceuticals Fourth Quarter and Full Year 2024 Financial Results Conference Call. At this time, all participants are in listen-only mode. Later ...

Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.52 per share. This compares to earnings of $0.02 per share a year ago.